ClinicalTrials.gg
Enrolling by invitationNCT06851403Updated Feb 28, 2025

The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study

An observational study in Asthma in Children, sponsored by Guangzhou Institute of Respiratory Disease. Enrolling by invitation at 1 site in China. Open to participants aged 4 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Guangzhou Institute of Respiratory Disease · Observational

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
213
Ages
4 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Asthma by Guangzhou Institute of Respiratory Disease — 1 open to participants now, 1 under way, none of them phase 3. Asthma · Guangzhou Institute of Respiratory Disease.

Started
2022
with 1 other
Observational
7 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in Asthma by Guangzhou Institute of Respiratory Disease, this one is one of 2 that started in 2022, is one of 7 observational ones, and was the 13th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 13 studies in Asthma by Guangzhou Institute of Respiratory Disease is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Asthma by Guangzhou Institute of Respiratory Disease, or all of them as a file.
02

Study summary

Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.

03

Conditions studied

  • Asthma in Children

Browse trials for

Keywords

  • type 2 inflammation
  • asthma
  • dupilumab
04

Who can participate

Ages eligible
4 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The attending physician evaluated these patients as having type 2 inflammatory asthma based on factors such as FeNO (fractional exhaled nitric oxide) levels ≥ 20, sputum eosinophils (EOS) percentage ≥ 2%, and/or blood EOS count ≥ 300/μl.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Enrolled patients were required to have been on regular ICS-LABA therapy for at least 3-6 months without adequate control. The attending physician evaluated these patients as having type 2 inflammatory asthma based on factors such as FeNO (fractional exhaled nitric oxide) levels ≥ 20, sputum eosinophils (EOS) percentage ≥ 2%, and/or blood EOS count ≥ 300/μl. All children were prescribed with dupilumab during the study period.

Exclusion criteria

Exclusion Criteria:

Patients with conditions other than asthma receiving treatment with dupilumab, individuals currently using other biologics or undergoing sublingual or subcutaneous immunotherapy, active parasitic infections, and children with immunodeficiency were excluded.

05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
213 participants (estimated)
Patient registry
No

Groups and cohorts

  • Case group

    Drug: Dupilumab

Interventions

  • initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks

06

What researchers measure

Primary outcomes

  1. FEV1

    forced expiratory volume in one second

    Time frame: From enrollment to the end of treatment through study completion, an average of 1 year

  2. FVC

    forced vital capacity

    Time frame: From enrollment to the end of treatment through study completion, an average of 1 year

  3. FEV1/FVC

    ratio of forced expiratory volume in onesecond to forced vital capacity

    Time frame: From enrollment to the end of treatment through study completion, an average of 1 year

  4. PEF

    peak expiratory flow

    Time frame: From enrollment to the end of treatment through study completion, an average of 1 year

Secondary outcomes

  1. FeNO

    fraction of exhaled nitric oxide

    Time frame: From enrollment to the end of treatment through study completion, an average of 1 year

  2. blood EOS

    blood eosinophil count

    Time frame: From enrollment to the end of treatment through study completion, an average of 1 year

  3. percentage of sputum eosinophils

    Time frame: From enrollment to the end of treatment through study completion, an average of 1 year

  4. TIgE

    serum total immunoglobulin E

    Time frame: From enrollment to the end of treatment through study completion, an average of 1 year

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2025, 47 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 47 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2024
First posted
Feb 28, 2025
StartActual
Jan 30, 2022
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06851403
Lead sponsor
Guangzhou Institute of Respiratory Disease
Responsible party
LI-HONG SUN (Guangzhou Institute of Respiratory Disease, Guangzhou Institute of Respiratory Disease) — Principal investigator
First posted
Feb 28, 2025
Start date
Jan 30, 2022
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Feb 28, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion